What’s in a name?
When it comes to the company, aphria is most closely associated with its aphrodisiacs, which include the “ladybug,” “sausage” and “spoon.”
The company is also known for its aphromantic products, which are used to treat insomnia and migraines.
In recent years, aphrosy has been a major player in the U.S. pharmaceutical industry, with sales of aphrohyte products soaring by over a half-billion dollars.
In fact, aphropy has been so profitable that the company has been able to grow its workforce and stock by as much as 150 percent in the last decade.
But in 2014, the company was fined $1 million for illegally advertising aphrocytes, a violation of the Food, Drug and Cosmetic Act.
The fines, which were imposed in April 2016, came after the FDA and the FDA’s Office of Inspector General found that aphropsy and other drugs had been illegally marketed to consumers and that the drugs did not meet the requirements for labeling and safety.
As a result, aphrias sales plummeted by 70 percent in 2017 and by a whopping 95 percent in 2018, according to Bloomberg.
While aphrosys sales have been relatively flat since 2019, the firm has seen its stock price drop by nearly a quarter since 2018, dropping from $9.75 to $2.70.
What’s going on?
In 2019, aphrotechs was acquired by AstraZeneca, which also bought the company’s trademark for “sugar pill.”
But the deal has not been entirely smooth, with Astra being sued for allegedly misrepresenting the efficacy of its sugar pill.
In 2017, the FDA sent letters to Astra and the other parties in the deal, alleging that Astra misrepresented the efficacy and safety of its “sugary” pill.
The letters cited numerous examples of Astra’s advertising that misrepresented that its pill was superior to others and that it was “better than other pill.”
According to Bloomberg, Astra had to pay $2 million in penalties and pay a $1.8 million civil penalty.
In addition to Astreas lawsuits, the other entities in the Aphrosy deal are the New York City-based Astra Pharmaceuticals, the Los Angeles-based Aphrosyn and Astra Laboratories, which is owned by Astralife, AstroSyn, and Astralia.
Astra was also the subject of an investigation into drug marketing by the New Jersey attorney general, and an investigation by the U